- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02653495
Impact of Metabolic Syndrome on Flu Vaccine Efficacy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The development of industrialization with increased food consumption and sedentarity has given rise to an obesity pandemic, which affects up to 30% of the population in countries like US, these populations being at greater risk for cardiovascular diseases, and diabetes. More than obesity per se, visceral obesity is associated with metabolic diseases that cluster together and clinically defined metabolic syndrome. MetS comprises individuals with at least three of the 5 of the following factors: abdominal obesity, high blood triglycerides, low HDL ("good cholesterol"), high blood pressure and elevated fasting glucose. Metabolic syndrome is associated with a low-grade inflammation characterized by an infiltration of immune cells particularly in the adipose tissue, the liver and the pancreas that is thought to be responsible for the induction of insulin resistance. It is thought that obesity predisposes to other diseases such as cancer, asthma but only little attention has been given to infectious diseases. Studies have shown that obesity increases the risk of severe influenza infection and associated death and reduces the efficacy of influenza vaccine in the obese population but yet, the molecular mechanisms have not been described. Immune dysfunctions associated with obesity are suspected to play a major role but obesity is often associated with respiratory disorders that could directly explain the increased susceptibility to influenza infection. Also, metabolically healthy obesity is less associated with inflammation. Therefore, the investigators would like to focus particularly on metabolic syndrome, and determine how it influences immune response to viruses.
The investigators are thus hypothesizing that differences in the innate immune responses between individual with or without metabolic syndrome impact viral infection and vaccine outcome. Recent studies involving complex biological analysis and computational modeling have shown that the ability of an individual to positively respond to influenza vaccine can be molecularly predicted by looking at markers in the blood cells. The investigators will perform seasonal influenza vaccination in people with or without metabolic syndrome to determine if the late adaptive response assessed by antibodies titers is different between the two groups and correlates with the early immune response assessed by gene expression profile in whole blood cells.
Healthy nutritional habits along with increased physical activities should be best at preventing the development of metabolic syndrome but socio-economical issues are slowing the implementation of these changes. Therefore, as metabolic syndrome is raising public health concerns, it is important to understand why the metabolic syndrome affects susceptibility to diseases.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Rockefeller University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria for the METABOLIC SYNDROME COHORT( Participants must have 3 or more of the following 5 risk factors):
- Abdominal Obesity, given as a waist circumference: Men >102 cm (>40 in) Women > 88 cm (>35 in)
- Triglycerides >150 mg/dl
- HDL Cholesterol: Men < 40 mg/dl Women < 50 mg/dl
- Blood Pressure >130/ >85 mm Hg - or controlled on antihypertensive medication
- Fasting Glucose > 100 mg/dl
Inclusion criteria for the HEALTHY CONTROLS (Participants must have all of the requirements below) :
- body mass index 18.5 - 25 kg/m2
- HDL female > 50 mg/dL, male > 40 mg/dL
- fasting glucose < 100 mg/dL
- triglycerides <150 mg/dL,
- waist circumference of a female < 88 cm, male < 102 cm)
- - Blood pressure < or = to 120/80 (based on an average of 3 readings taken 5 minutes apart after the consent form has been signed)
Exclusion criteria :
- Currently undergoing treatment for the metabolic syndrome
- The average of 2 BP readings > 150/90 (based on 2 B/Ps taken at screening visit 1).
- Hepatitis A, B and C
- NSAIDs and/or Aspirin ingestion within the last 14 days
- Self-reported history of any active autoimmune diseases
- Self-reported ingestion of statins within the last 3 months
- Self-reported antibiotic use within the last 3 months
- Anti-inflammatory drugs including biologics and corticosteroids within last 3 months( nasal spray and topical applications are OK)or Omega 3 Fatty Acids.
- Self-reported hx of cancer treatment within the last year
- Allergy to eggs
- History of Guillain-Barre syndrome
- Pregnant ( determined by point of care testing at screening visit 1).
- HIV positive
- Self-reported history of flu vaccination within the past 3 months.
- Any self-reported infection in the week of the visit except the first two visits (Screening visit 1 and Screening visit 2) and the last visit (Study visit #5) that could be rescheduled.
- Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.
Study Population Description The population from which the groups will be selected are resident of New York City.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Influenza vaccine in metabolic syndrome
Influenza vaccine
|
Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
|
Experimental: Influenza vaccine in healthy controls
Influenza vaccine
|
Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antibody Response D28
Time Frame: 28 days after vaccination compare to baseline (screening visit 1) pre-vaccination
|
Measured by hemagglutination inhibition assay
|
28 days after vaccination compare to baseline (screening visit 1) pre-vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gene Expression Profiling D1
Time Frame: 1 day post-vaccination compare to baseline (gene expression screening visit #1 and study visit #1 D0 of vaccination)
|
Analyze by RNA-seq
|
1 day post-vaccination compare to baseline (gene expression screening visit #1 and study visit #1 D0 of vaccination)
|
Gene Expression Profiling D28
Time Frame: 28 days post-vaccination compare to baseline (gene expression screening visit #1 and study visit #1 D0 of vaccination)
|
Analyze by RNA-seq
|
28 days post-vaccination compare to baseline (gene expression screening visit #1 and study visit #1 D0 of vaccination)
|
Gene Expression Profiling D90
Time Frame: 90 days post-vaccination compare to baseline (gene expression screening visit #1 and study visit #1 D0 of vaccination)
|
Analyze by RNA-seq
|
90 days post-vaccination compare to baseline (gene expression screening visit #1 and study visit #1 D0 of vaccination)
|
Antibody Response D90
Time Frame: 90 days after vaccination compare to day 28
|
Measured by hemagglutination inhibition assay
|
90 days after vaccination compare to day 28
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ursula Andreo, PhD, The Rockefeller University Center for Clinical and Translational
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UAN-0891
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Mayo ClinicCompleted
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Influenza vaccine
-
Novartis VaccinesCompleted
-
University of RochesterNational Institutes of Health (NIH)Withdrawn2009 H1N1 InfluenzaUnited States
-
Emory UniversityRecruitingFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin LymphomaUnited States
-
Masonic Cancer Center, University of MinnesotaTerminatedHematologic Malignancy | Hematopoietic Stem Cell TransplantUnited States
-
Sinovac Biotech Co., LtdRecruitingA Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 MonthsSeasonal InfluenzaChina
-
Sinovac Biotech Co., LtdRecruitingSeasonal InfluenzaChina
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Novartis VaccinesCompleted
-
NovartisNovartis VaccinesCompletedInfluenza InfectionSwitzerland